Improved survival to hospital discharge in pediatric in-hospital cardiac arrest using 2 Joules/kilogram as first defibrillation dose for initial pulseless ventricular arrhythmia.


Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
08 2020
Historique:
received: 12 01 2020
revised: 18 05 2020
accepted: 26 05 2020
pubmed: 12 6 2020
medline: 22 6 2021
entrez: 12 6 2020
Statut: ppublish

Résumé

The American Heart Association (AHA) recommends first defibrillation energy dose of 2 Joules/kilogram (J/kg) for pediatric cardiac arrest with ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT). However, optimal first energy dose remains unclear. Using AHA Get With the Guidelines-Resuscitation® (GWTG-R) database, we identified children ≤12 years with IHCA due to VF/pVT. Primary exposure was energy dose in J/kg. We categorized energy doses: 1.7-2.5 J/kg as reference (reflecting 2 J/kg intended dose), <1.7 J/kg and >2.5 J/kg. We compared survival for reference doses to all other doses. We constructed models to test association of energy dose with survival; adjusting for age, location, illness category, initial rhythm and vasoactive medications. We identified 301 patients ≤12 years with index IHCA and initial VF/pVT. Survival to discharge was significantly lower with energy doses other than 1.7-2.5 J/kg. Individual dose categories of <1.7 J/kg or >2.5 J/kg were not associated with differences in survival. For patients with initial VF, doses >2.5 J/kg had worse survival compared to reference. For all patients ≤18 years (n = 422), there were no differences in survival between dosing categories. However, all ≤18 with initial VF receiving >2.5 J/kg had worse survival. First energy doses other than 1.7-2.5 J/kg are associated with lower rate of survival to hospital discharge in patients ≤12 years old with initial VF/pVT, and first doses >2.5 J/kg had lower survival rates in all patients ≤18 years old with initial VF. These results support current AHA guidelines for first pediatric defibrillation energy dose of 2 J/kg.

Identifiants

pubmed: 32522702
pii: S0300-9572(20)30231-8
doi: 10.1016/j.resuscitation.2020.05.048
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-96

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Derek B Hoyme (DB)

Department of Pediatrics, University of Wisconsin-Madison School of Medicine and Biomedical Sciences, Madison, WI, USA. Electronic address: dhoyme@wisc.edu.

Yunshu Zhou (Y)

Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.

Saket Girotra (S)

Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Sarah E Haskell (SE)

Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Ricardo A Samson (RA)

Children's Heart Center of Nevada, Department of Pediatrics, University of Nevada-Las Vegas School of Medicine, Las Vegas, NV, USA.

Peter Meaney (P)

Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.

Marc Berg (M)

Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.

Vinay M Nadkarni (VM)

The Children's Hospital of Philadelphia, Department of Anesthesiology and Critical Care Medicine, Philadelphia, PA, USA.

Robert A Berg (RA)

The Children's Hospital of Philadelphia, Department of Anesthesiology and Critical Care Medicine, Philadelphia, PA, USA.

Mary Fran Hazinski (MF)

Vanderbilt University School of Nursing, Nashville, TN, USA.

Javier J Lasa (JJ)

Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.

Dianne L Atkins (DL)

Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH